ERBB2 and breast carcinoma: The results not only provide a reference for clinical assessment of the reasons for refusing or discontinuing treatment among HER2 breast cancer patients in China, but also bring insights into strengthening the health system in the other developing settings, in order to help cancer patients to overcome the suffering encountered during treatment.